AOTMiT: Transparency Council on menopause, target import and reimbursement in off-label indications, among others

Agenda:

• 1. veoza (fezolinetantum) for the indication: treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause

Decision-making problem: preparing a position on target imports (Article 39)

2.Milupa Basic F in indications:

• CACT deficit,
• VLCAD deficit,
• Lymphadenopathy (including conditions after cardiac surgery),
• abetalipoproteinemia,
• Lipid metabolism disorders (hypercholesterolemia and hypertriglyceridemia), lipoprotein lipase deficiency.

Decision-making problem: preparing a position on target imports (Article 39)

3. Ferriprox (deferipronum) for the indication: neurodegeneration with iron deposition in the brain.

Decision-making problem: preparing a position on target imports (Article 39)

4. "Prevention of early detection of eye defects and strabismus in children aged 5-6 years" (m. Stalowa Wola)

Decision-making problem: preparing an opinion on the draft health policy program of a local government unit (Article 48a).

5. "Prophylaxis and early detection of prostate cancer among residents of Polkowice municipality".

Decision-making problem: preparing an opinion on the draft health policy program of a local government unit (Article 48a).

6 Azathioprinum in indications:

• Inflammatory bowel disease other than of autoimmune origin - in children under 18 years of age;
• IgA nephropathy other than of autoimmune origin - in children under 18 years of age;
• Vasculitis other than of autoimmune origin - in children under 18 years of age.

Decision-making problem: preparation of an opinion on the continuation of reimbursement in off-label indications (Article 40).

1. Theophyllinum for the indication: bradycardia in children under 18 years of age.

Decision-making problem: preparation of an opinion on the continuation of reimbursement in off-label indications (Article 40).

1. Phenoxymethylpenicillinum in indications:

• Infections in patients after autologous or allogeneic bone marrow transplantation - prevention;
• Infections in immunocompromised patients - prevention;
• Infections in patients with hematopoietic proliferative diseases - prevention.

Decision-making problem: preparation of an opinion on the continuation of reimbursement in off-label indications (Article 40).

1. Ciclosporinum in indications:

• Autoimmune diseases other than those specified in the SmPC;
• Alport syndrome with proteinuria in children under 18 years of age;
• Aplastic anemia in children under 18 years of age;
• Inflammatory bowel disease in children under 18 years of age.

Decision-making problem: preparation of an opinion on the continuation of reimbursement in off-label indications (Article 40).

Source: AOTMIT